CdK5, OX40, and Immune Tolerance in Uveitis
CdK5, OX40, and Immune Tolerance in Uveitis
批准号:
8812858
负责人:
John James Letterio
金额:
$39.22万
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-03-01 至 2016-02-29
关键词:
AblationAdoptive TransferAffectAnimal ModelAntigensApoptosisAttenuatedBCL2 geneBlindnessBlocking AntibodiesCD4 Positive T LymphocytesCellsCellular biologyCyclin-Dependent Kinase 5DiseaseEconomicsEyeEye diseasesFundingGoalsHealthHumanImmune ToleranceInduction of ApoptosisInfiltrationInflammationInflammatoryKineticsKnockout MiceLeadLymphocyteMediatingModelingMolecularMusOvalbuminPathogenesisPlayPopulationProtein-Serine-Threonine KinasesProteinsRecombinantsRegulationRelapseReportingRoleSeveritiesSignal TransductionSocial WelfareSocietiesSpleenStagingSystemT cell anergyT cell responseT-Cell ActivationT-LymphocyteTNFSF4 geneTestingTherapeuticTransfectionTreatment EfficacyUveitisWild Type Mouseanergyautoimmune uveitisbasecytokineinhibitor/antagonistlymph nodesnovelnovel strategiesolomoucinepreventpromoterrecombinaseroscovitinetherapeutic target
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Uveitis is a common eye disorder with relapsing and serious inflammation. Aberrant T cell response plays a central role in the pathogenesis of uveitis. OX40 is a key co-stimulatory molecule essential for T cell activation function and survival. However, the key downstream molecules executing this critical co-stimulation signal remain to be fully elucidated. Our overall goal is to better understand the immunopathological mechanism of uveitis and further test the novel strategy of inducing immune tolerance for the treatment of ocular inflammation. Recently, we have shown that OX40 is up-regulated in both human uveitis and animal models, whereas blocking OX40 signaling attenuates ocular inflammation. In addition, our preliminary study suggests that OX40 signaling influences the expression of cyclin-dependent kinase 5 (CdK5), a unique protein that has been recently implicated in T cell biology. Furthermore, blocking CdK5 attenuates OX40-enhanced ocular inflammation. Based on above findings, we postulate that CdK5 is a critical intermediary of OX40 co- stimulation, leading to exaggerated uveitis by reducing T cell apoptosis and/or anergy. To test this hypothesis, we propose (1) to determine the expression kinetics of OX40 and CdK5 in experimental uveitis models and the impact of OX40 activation on CdK5 regulation; (2) to test CdK5 as a key intermediary of OX40 co-stimulation using Cre-loxP recombinase system and examine the therapeutic efficacy of CdK5-targeting treatment for ocular inflammation; (3) to define the molecular mechanism by which CdK5 facilitates OX40 action in preventing T cell apoptosis and anergy in uveitis.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Small Molecule Induction of 15-PGDH: A Target in Colon Cancer Chemoprevention
-
批准号:9248208
-
项目类别:
-
资助金额:$32.89万
-
财政年份:2013
-
负责人:John James Letterio
-
依托单位:
Small Molecule Induction of 15-PGDH: A Target in Colon Cancer Chemoprevention
-
批准号:9040105
-
项目类别:
-
资助金额:$32.89万
-
财政年份:2013
-
负责人:John James Letterio
-
依托单位:
Small Molecule Induction of 15-PGDH: A Target in Colon Cancer Chemoprevention
-
批准号:8828504
-
项目类别:
-
资助金额:$32.89万
-
财政年份:2013
-
负责人:John James Letterio
-
依托单位:
CdK5, OX40, and Immune Tolerance in Uveitis
-
批准号:9053492
-
项目类别:
-
资助金额:$39.66万
-
财政年份:2013
-
负责人:John James Letterio
-
依托单位:
Small Molecule Induction of 15-PGDH: A Target in Colon Cancer Chemoprevention
-
批准号:8505851
-
项目类别:
-
资助金额:$32.81万
-
财政年份:2013
-
负责人:John James Letterio
-
依托单位:
CdK5, OX40, and Immune Tolerance in Uveitis
-
批准号:8628128
-
项目类别:
-
资助金额:$39.22万
-
财政年份:2013
-
负责人:John James Letterio
-
依托单位:
CdK5, OX40, and Immune Tolerance in Uveitis
-
批准号:8419629
-
项目类别:
-
资助金额:$41.35万
-
财政年份:2013
-
负责人:John James Letterio
-
依托单位:
DISCOVERY AND EVALUATION OF NOVEL TRITERPENOID CHEMOPREVENTIVES IN A NEW COLON CA
-
批准号:7545051
-
项目类别:
-
资助金额:$7.84万
-
财政年份:2008
-
负责人:John James Letterio
-
依托单位:
DISCOVERY AND EVALUATION OF NOVEL TRITERPENOID CHEMOPREVENTIVES IN A NEW COLON CA
-
批准号:7641064
-
项目类别:
-
资助金额:$7.85万
-
财政年份:2008
-
负责人:John James Letterio
-
依托单位:
Developmental Therapeutics Research Program
-
批准号:10380717
-
项目类别:
-
资助金额:$5.51万
-
财政年份:1997
-
负责人:John James Letterio
-
依托单位:
Developmental Therapeutics Research Program
-
批准号:10784825
-
项目类别:
-
资助金额:$9.32万
-
财政年份:1997
-
负责人:John James Letterio
-
依托单位:
Developmental Therapeutics Research Program
-
批准号:9904162
-
项目类别:
-
资助金额:$5.1万
-
财政年份:--
-
负责人:John James Letterio
-
依托单位:
海外基金